Merck

Four Democratic senators want to know whether Kennedy or his family retained financial interests in the Merck vaccine litigation he helped build before taking over HHS.

Moderna stock soared on positive Phase 3 results for its personalized melanoma vaccine with Merck, prompting Morgan Stanley to raise its price target to $89 from $39.

Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.